Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial

What Was Tested

This randomized controlled trial paper looks at Petrelintide.

Petrelintide is a novel, long-acting amylin analogue being developed for long-term treatment of obesity, leveraging a mechanism of action distinct from incretin-based treatments.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and multicenter.

Random assignment meant chance, not the researchers, decided who got Petrelintide and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Petrelintide.

The comparison arm used a placebo, so changes seen with Petrelintide could be set against what happens without it.

Running at several centres spread the Petrelintide study over different clinics and patient groups.

The timeline in the abstract includes 28 weeks.

This multicentre, randomised, double-blind, placebo-controlled trial involved 32 sites (public hospitals and private clinics) in Poland, Romania, and the USA.

Randomisation was done via a central interactive response technology system and was stratified by MRI participation.

The primary endpoint was percentage change in bodyweight from baseline after 28 weeks.

Missing data were assumed to be missing at random.

The trial is registered with ClinicalTrials.gov (NCT06662539) and the Clinical Trials Information System (2024-512549-18) and was completed on Mar 7, 2026.

What Was Measured

PubMed files the paper under topics including Obesity and Islet Amyloid Polypeptide.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Petrelintide over 28 weeks.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (The lancet. Diabetes & endocrinology), a journal based in England.

More context: the Petrelintide compound page, all human trials.